Breaking News Instant updates and real-time market news.

EA

Electronic Arts

$102.37

5.1 (5.24%)

, ATVI

Activision Blizzard

$41.68

1.57 (3.91%)

07:35
02/13/19
02/13
07:35
02/13/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Tuesday in Electronic Arts (EA), Activision Blizzard (ATVI), Wal-Mart (WMT), Wynn Resorts (WYNN), Xilinx (XLNX), Nike (NKE), Caesars (CZR), ArcelorMittal (MT), Viking Therapeutics (VKTX), and NetApp (NTAP).

EA

Electronic Arts

$102.37

5.1 (5.24%)

ATVI

Activision Blizzard

$41.68

1.57 (3.91%)

WMT

Walmart

$96.96

0.76 (0.79%)

WYNN

Wynn Resorts

$126.16

1.13 (0.90%)

XLNX

Xilinx

$118.15

3.26 (2.84%)

NKE

Nike

$84.73

1.06 (1.27%)

CZR

Caesars

$9.42

(0.00%)

MT

ArcelorMittal

$21.95

0.43 (2.00%)

VKTX

Viking Therapeutics

$8.97

0.86 (10.60%)

NTAP

NetApp

$67.13

1.21 (1.84%)

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 15

    Feb

  • 19

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

  • 06

    Mar

EA Electronic Arts
$102.37

5.1 (5.24%)

02/13/19
RHCO
02/13/19
NO CHANGE
Target $49
RHCO
Buy
Activision Blizzard price target lowered to $49 from $54 at SunTrust
SunTrust analyst Matthew Thornton lowered his price target on Activision Blizzard (ATVI) to $49, saying the company's reported quarter and guidance were "clearly challenged", with added risk coming from the rising popularity of Electronic Arts' (EA) Apex Legends. The analyst also keeps his Buy rating on the stock, noting that some of its uncertainty has been removed while the management is increasing development investment to accelerate new content. Thornton lowers his FY19 and FY20 EPS by 42c and 43c to $2.25 and $2.50 respectively, adding that his new valuation multiples are in in with historical average and may prove conservative.
02/11/19
BARD
02/11/19
NO CHANGE
Target $106
BARD
Outperform
Electronic Arts price target raised to $106 from $90 at Baird
Baird analyst Colin Sebastian raised his price target on Electronic Arts to $106 and kept his Outperform rating after the company disclosed today that the number of active Apex Legends players has topped 25M since its launch. The analyst states that the launch implies a better start the the "phenom" Fortnite game, which took over 40 days to reach 25M users, adding that while the data on player retention and monetization is limited, an upcoming update from Respawn should give investors more visibility on whether Apex will be a hit.
02/11/19
02/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Canaccord with analyst Jed Dorsheimer saying he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. 2. Avis Budget (CAR) upgraded to Buy from Sell at Goldman Sachs with analyst David Tamberrino saying trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion. 3. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing the surprise start to Apex Legends' new Battle Royale. 4. Hasbro (HAS) upgraded to Buy from Neutral at Monness Crespi. 5. Lloyds Banking (LYG) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/11/19
JEFF
02/11/19
NO CHANGE
Target $90
JEFF
Buy
Electronic Arts price target raised to $90 from $80 at Jefferies
Jefferies analyst Timothy O'Shea raised his price target for Electronic Arts to $90 saying Titanfall Apex Legends is the company's "hottest new game in years." The game is a free battle royale game that seeks to capitalize on the same trends that propelled Fortnite to $2.4B of revenue in 2018, O'Shea tells investors in a research note. He keeps a Buy rating on shares of Electronic Arts.
ATVI Activision Blizzard
$41.68

1.57 (3.91%)

02/13/19
JPMS
02/13/19
NO CHANGE
Target $58
JPMS
Overweight
Activision Blizzard longer term outlook remains favorable, says JPMorgan
JPMorgan analyst Alexia Quadrani lowered her price target for Activision Blizzard to $58 from $63 and keeps an Overweight rating on the shares following the company's Q4 results. The stock may be range bound for the near term given a lack of catalysts and limited view into how in-game services are trending for Call of Duty, Hearthstone, and Overwatch, Quadrani tells investors in a research note. However, her overall thesis though remains unchanged as she remains confident that investors will shift their focus throughout 2019 to the long-term fundamentals supporting the sector, and the 2020 outlook, which is "very likely to include a World of Warcraft expansion and full year of Diablo Immortal." Further, Activision remains a stock with "significant long-term optionality not built into consensus estimates," says Quadrani. The analyst views Activision Blizzard's long-term outlook as favorable.
02/13/19
MKMP
02/13/19
NO CHANGE
Target $45
MKMP
Neutral
Activision Blizzard price target lowered to $45 from $48 at MKM Partners
MKM Partners analyst Eric Handler lowered his price target on Activision Blizzard to $45 and kept his Neutral rating after its "lacking" Q4 revenue and disappointing FY19 outlook. The analyst notes that the company's non-development and administrative cost reductions, as well as elimination of underperforming title investment, are "severely needed", but sees the timeline on these revitalization efforts as unclear. Handler reduces his FY19 EPS view for Activision Blizzard to $2.16 from $2.40, adding that the uncertainty is also weighing on his outlook for FY20.
02/13/19
BARD
02/13/19
NO CHANGE
Target $58
BARD
Outperform
Activision Blizzard price target lowered to $58 from $69 at Baird
Baird analyst Colin Sebastian lowered his price target on Activision Blizzard to $58 from $69 following Q4 results. The analyst said management announced several strategic changes and a revamped corporate structure as well as provided guidance which reflect headwinds for "Call of Duty" and in-game transactions for Blizzard franchises. Despite ongoing execution risks, he believes management's sense of urgency is justified and should translate into improving digital growth. Sebastian maintained his Outperform rating on Activision Blizzard shares.
WMT Walmart
$96.96

0.76 (0.79%)

02/07/19
BUCK
02/07/19
INITIATION
BUCK
Neutral
Walmart reinstated with a Neutral at Buckingham
02/13/19
BARD
02/13/19
NO CHANGE
Target $110
BARD
Outperform
Walmart investors should stay involved, says Baird
Baird analyst Peter Benedict previewed Walmart's Q4 earnings report, which he expects to be solid. The analyst recommends investors stay involved as he believes the company's U.S. strategy of investing in people, processes, and technology is resonating with customers. The analyst said a convergence of initiatives should help sustain momentum and he sees continued progress on expenses. He expects guidance to remain intact, although he recognizes the uncertainty with Flipkart as the result of new regulations in India. Benedict reiterated his Outperform rating and $110 price target on Walmart shares.
02/07/19
BUCK
02/07/19
INITIATION
Target $109
BUCK
Neutral
Walmart initiated with a Neutral at Buckingham
Buckingham analyst Bob Summers started Walmart with a Neutral rating and $109 price target. The analyst views Walmart as one of the best positioned companies in all of retail but believes "current and future successes" are well reflected in current valuation levels. He "would be compelled" to revisit his rating on a significant share pullback.
02/08/19
02/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Airlines (AAL) initiated with a Hold at Argus. 2. Walmart (WMT) and Sprouts Farmers Market (SFM) were initiated with a Neutral at Buckingham, while Kroger (KR) was initiated with an Underperform. 3. Wrap Technologies (WRTC) initiated with a Buy at Chardan. 4. nLight (LASR) initiated with a Hold at Craig-Hallum. 5. RA Pharmaceuticals (RARX) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WYNN Wynn Resorts
$126.16

1.13 (0.90%)

01/31/19
DBAB
01/31/19
NO CHANGE
Target $145
DBAB
Buy
Wynn Resorts price target raised to $145 from $130 at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli raised his price target for Wynn Resorts to $145 saying the company's "solid" Q4 results and "firmer tone" bode well for the shares. The analyst points out that Wynn delivered "healthy upside" to his property level forecasts with Macau results exceeding our estimate by $34M. He keeps a Buy rating on the shares.
01/31/19
STFL
01/31/19
NO CHANGE
Target $146
STFL
Buy
Wynn Resorts quarter broadly better than expected, says Stifel
Stifel analyst Steven Wieczynski said Wynn Resorts posted a broadly better than expected quarter, with Macau results that were well ahead of management's guidance on the last earnings call and domestic results that also beat his forecast and consensus. While Wieczynski does not expect Q4 earnings to serve as an inflection point for sentiment given several uncertainties Wynn faces in the near-term, he remains upbeat on the prospects for Wynn shares to deliver outsized returns over the long-term. He keeps a Buy rating on Wynn shares and raised his price target to $146 from $141.
01/31/19
ROTH
01/31/19
NO CHANGE
Target $135
ROTH
Buy
Wynn Resorts price target lowered to $135 from $140 at Roth Capital
Roth Capital analyst David Bain lowered his price target for Wynn Resorts to $135 form $140 as he believes its position in Macau is slightly weaker given market trends. Wynn carries the second lowest room count in a Macau market transitioning to a reliance break-out visitation to meet expectations and declining market VIP play, which it remains more levered to than peers, he notes. Bain reiterates a Buy rating on the shares, citing forward catalysts and visibility of increasing shareholder capital returns.
01/31/19
NOMU
01/31/19
NO CHANGE
Target $145
NOMU
Buy
Wynn Resorts price target raised to $145 from $132 at Nomura Instinet
Nomura Instinet analyst Harry Curtis raised his price target for Wynn Resorts to $145 saying the company delivered even stronger Q4 results than his above-consensus forecasts. The analyst keeps a Buy rating on the shares.
XLNX Xilinx
$118.15

3.26 (2.84%)

01/24/19
MKMP
01/24/19
NO CHANGE
Target $95
MKMP
Neutral
Xilinx price target raised to $95 from $85 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Xilinx to $95 after its better than expected Q3 results showed broad-based strength across most end market segments. The analyst also notes the company's better than expected outlook for Q4 and believes that Xilinx is "benefiting from various new product and end market ramps as well as continued market share gains". Roy keeps his Neutral rating on the shares however, stating that the upside from the company's high medium-term expectations is priced in.
01/24/19
BMOC
01/24/19
NO CHANGE
Target $100
BMOC
Outperform
Xilinx price target raised to $100 from $90 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Xilinx to $100 and kept his Outperform rating after its Q3 earnings, saying the company "delivered on another quarter of solid results and guidance." The analyst notes that the company's wireless communications is "clearly helping as 5G deployments take hold", and also points to the strength of Xilinx's overall advanced product line-up. Srivastava further cites the company's operating margins remaining comfortably above 30% thanks to its operating expense discipline and top-line growth.
01/25/19
ARGS
01/25/19
NO CHANGE
Target $130
ARGS
Buy
Xilinx price target raised to $130 from $110 at Argus
Argus analyst Jim Kelleher raised his price target on Xilinx to $130 and kept his Buy rating, saying the company's Q3 results were strong and Q4 guidance "robust" just some of its semiconductor peers are posting negative comparisons and reducing expectations. The analyst notes that the end-market demand in communications is especially strong, with more carriers starting to build out their 5G infrastructure. While Xilinx has already "outperformed most semiconductor stocks amid tech-sector weakness", Kelleher believes that its "superior growth prospects" signal good value.
02/04/19
GSCO
02/04/19
DOWNGRADE
Target $122
GSCO
Buy
Xilinx downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Toshiya Hari removed Xlinx from the firm's Conviction List while maintaining a Buy rating, telling investors in a research note that the stock is up 51% since it was added to the Conviction List on January 5, 2018, during which the medium semiconductor stock under coverage was flat. Hari says he thinks Xilinx's favorable end-market exposure, growth opportunity in 5G and early traction in the data center market are now better understood by investors. Hari says his updated $122 price target implies 9% potential upside.
NKE Nike
$84.73

1.06 (1.27%)

01/25/19
JEFF
01/25/19
NO CHANGE
Target $67
JEFF
Buy
Foot Locker price target raised to $67 from $62 at Jefferies
Jefferies analyst Janine Stichter raised her price target for Foot Locker to $67 to reflect increased conviction that the company's business continues to gain momentum. Data the analyst looks at point to a Nike (NKE) resurgence in North America, "rising heat" around basketball and Jordans, a "healthy" innovation pipeline, and "controlled" promotions. The analyst still sees opportunity in Foot Locker shares despite the recent rally and keeps a Buy rating on the name.
02/08/19
OPCO
02/08/19
NO CHANGE
Target $100
OPCO
Outperform
Nike price target raised to $100 from $90 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target on Nike to $100 while reiterating it as a Top Pick, telling investors in a research note that he is "even more impressed" with the company's underlying operating prowess than he was after upgrading shares in October to Outperform. In addition to strong top-line dynamics, tighter inventory management globally continues to result in improved full price sell-through, unlocking margin upside in the Nike model, Nagel contends.
01/25/19
JEFF
01/25/19
NO CHANGE
JEFF
Under Armour discounting down for tenth straight month, says Jefferies
Jefferies analyst Randal Konik says his firm's January webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is down for the tenth month in a row year-over-year, while Adidas's (ADDYY) percentage is up for the eleventh month in a row. Further, Visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR, Project Rock, and Curry 6 are sold out in several sizes, indicating strong demand, Konik tells investors in a research note. He also believes that Nike (NKE) continues to dominate Adidas in running in the U.S.
01/24/19
MSCO
01/24/19
NO CHANGE
Target $103
MSCO
Overweight
Nike likely to gain most of Adidas' lost share, says Morgan Stanley
Noting that Morgan Stanley's European Brands analyst Elena Mariani believes the market is underestimating the cyclicality of Adidas' (ADDYY) business and downgraded the stock this morning to Underweight, Morgan Stanley analyst Lauren Cassel said she believes Adidas' recent slowdown can be directly linked to Nike's (NKE) aggressive comeback and "impressive innovation pipeline." Should Adidas face increasing sales pressure, Cassel would expect much of its share loss to be captured by Nike, she tells investors. The firm's Asia apparel/footwear OEMs analyst's channel checks suggest Adidas' footwear orders have been very volatile of late, which might reflect weakening end-demand. Meanwhile, the channel checks suggest the opposite for Nike, as they point to strong, consistent orders, Cassel said. She keeps an Overweight rating and $103 price target on Nike shares.
CZR Caesars
$9.42

(0.00%)

01/16/19
BOFA
01/16/19
DOWNGRADE
Target $9
BOFA
Neutral
Caesars downgraded to Neutral following rally at BofA/Merrill
BofA/Merrill analyst Shaun Kelley downgraded Caesars to Neutral from Buy and lowered its price target to $9. Kelley is using the rally year-to-date in shares to downgrade saying he is more cautious longer-term towards Las Vegas pricing power and growth.
01/18/19
MSCO
01/18/19
NO CHANGE
MSCO
Overweight
Morgan Stanley prefers Las Vegas to Macau in gaming entering 2019
Morgan Stanley analyst Thomas Allen said he is confident that the Las Vegas outlook is better than perceived after Q4 appears to have shown a meaningful rebound, noting also that his convention tracker supports strong 2019 demand growth and that flight capacity to the market is growing. Meanwhile, as a firm, Morgan Stanley has cut its Macau market gaming revenue outlook and industry view, Allen noted. Combining his Las Vegas outlook and bullish stance on regional U.S. gaming, Allen called MGM Resorts (MGM) and Caesars (CZR) his preferred large cap gaming stocks entering 2019, stating that he believes expectations for both are beatable. He reiterates Overweight ratings on both, as well as on Las Vegas Sands (LVS), and keeps an Equal Weight rating on Wynn Resorts (WYNN).
01/07/19
DBAB
01/07/19
NO CHANGE
DBAB
Wynn, Caesars best large-cap Gaming stocks for 2019, says Deutsche Bank
Deutsche Bank analyst Carlo Santarelli says Wynn Resorts (WYNN) and Caesars Entertainment (CZR) are the best ways to play the large-cap Gaming space in 2019. Given current valuations and fundamental expectations "that seemingly accompany those valuations," the analyst is constructive on the larger-cap Gaming names and sees a bias to the upside in the stocks.
01/02/19
UBSW
01/02/19
UPGRADE
Target $7
UBSW
Neutral
Caesars upgraded to Neutral from Sell at UBS
UBS analyst Robin Farley upgraded Caesars Entertainment to Neutral while lowering her price target for the shares to $7 from $9. The analyst says her "bearish thesis" is now priced in with the stock down 33% over the past three months. Farley believes her below-consensus view on the Las Vegas market is more factored into the stock at these levels.
MT ArcelorMittal
$21.95

0.43 (2.00%)

06/07/18
UBSW
06/07/18
DOWNGRADE
UBSW
Sell
ArcelorMittal downgraded to Sell from Buy at UBS
11/09/18
UBSW
11/09/18
UPGRADE
UBSW
Neutral
ArcelorMittal upgraded to Neutral from Sell at UBS
04/30/18
JPMS
04/30/18
DOWNGRADE
JPMS
Neutral
Outokumpu downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Luke Nelson downgraded Outokumpu (OUTKY) to Neutral and lowered his price target for the shares to EUR 6 from EUR 11.60. ArcelorMittal (MT) remains the analyst's top pick in European Steel.
01/30/19
GSCO
01/30/19
DOWNGRADE
GSCO
Neutral
ArcelorMittal downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Eugene King downgraded ArcelorMittal to Neutral and lowered his price target to EUR22.50 from EUR35.50.
VKTX Viking Therapeutics
$8.97

0.86 (10.60%)

12/12/18
RILY
12/12/18
INITIATION
RILY
B. Riley FBR rolls out coverage on NASH players with three Buy ratings
B. Riley FBR analyst Mayank Mamtani last night initiated coverage of four companies working on developing drugs to treat nonalcoholic steatohepatitis. The analyst started Galmed Pharmaceuticals (GLMD) with a Buy rating and $28 price target, Intercept Pharmaceuticals (ICPT) with a Buy rating and $155 price target, Viking Therapeutics (VKTX) with a Buy rating and $16 price target, and Madrigal Pharmaceuticals (MDGL) with a Neutral rating and $124 price target. NASH disease burden is "poised to create the next liver transplant crisis" and is drawing significant investments from the biotech industry, Mamtani writes in a research note. He points out that Intercept's obeticholic acid is the only NASH drug to have the FDA's breakthrough therapy designation for strong anti-fibrotic efficacy and be previously approved by the FDA, for an orphan liver indication. His proprietary safety analysis suggests the Street should gain comfort in drug's cardiovascular profile going into pivotal readout in Q2 of 2019. Mamtani believes Viking's lead drug, VK2809, has an "excellent" safety and tolerability profile that assuages concerns of any off-target effects. Further, his comparator analysis suggests efficacy in high-dose of Galmed's Aramchol drug "represents a compelling clinical profile on both regulatory acceptable endpoints."
02/12/19
WBLR
02/12/19
NO CHANGE
WBLR
Viking could emerge as 'prime' buyout target for Gilead, says William Blair
Given Gilead Sciences' (GILD) leadership position in liver diseases and the significant resources that the company has devoted in the development of nonalcoholic steatohepatitis, last night's clinical setback "will likely reinvigorate" the company's willingness to augment its NASH pipeline, William Blair analyst Andy Hsieh tells investors in a research note. The analyst believes Gilead's Phase 3 failure could have a positive read-through to Viking Therapeutics (VKTX), which he notes is one of the only two beta-selective thyroid hormone receptor agonists in clinical testing. Viking's VK2809 demonstrated highly competitive data in reducing liver fat while maintaining a benign tolerability profile, Hsieh contends. Pending positive results from the company's Phase IIb study involving biopsy-confirmed NASH patients, he believes Viking Therapeutics "could emerge as a prime M&A target." The analyst keeps an Outperform rating on the shares. Viking in premarket trading is up 7% to $8.71.
01/17/19
RILY
01/17/19
NO CHANGE
Target $16
RILY
Buy
Viking selloff on Citron's Ligand report overdone, says B. Riley FBR
B. Riley FBR analyst Mayank Mamtani views the selloff yesterday in shares of Viking Therapeutics (VKTX) after Citron Research published a short report on Ligand Pharmaceuticals (LGND), the company's largest shareholder, as overdone. Interestingly, Ligand values Viking at a 10 times higher valuation than current trading levels, Mamtani tells investors in a research note. The analyst, whose firm does not cover Ligand, believes the report supports his thesis of Viking being an undervalued nonalcoholic steatohepatitis story. Additionally, competitor Lipocine's (LPCN) fat reduction data this morning, "while surprisingly positive," fell short of meeting/exceeding the 10.6% absolute fat reduction data reported from Viking in a Phase IIa study of early NASH patients, says Mamtani. He believes Viking Therapeutics maintains its "best in class status" and reiterates a Buy rating on the shares with a $16 price target. The stock in atfernoon trading is up 4%, or 35c, to $8.35.
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NTAP NetApp
$67.13

1.21 (1.84%)

02/08/19
OTRG
02/08/19
DOWNGRADE
OTRG
Mixed
NetApp downgraded to Mixed from Positive at OTR Global
01/16/19
01/16/19
NO CHANGE

Morgan Stanley downgrades IT Hardware industry view, shakes up ratings
Morgan Stanley analyst Kathryn Huberty downgraded her IT Hardware industry view to In-Line from Attractive, noting that hardware spending plans downticked more than any other technology category and across U.S. and European CIOs in the firm's recent checks. Slowing growth, which she attributes to waning cyclical benefits, makes it more difficult to own hardware-heavy data center stocks in the near-term, Huberty tells investors. As previously reported, Huberty downgraded HP Enterprise (HPE) to Equal Weight from Overweight and lowered her price target to $15 from $21, telling investors she thinks it's prudent to take a more cautious near-term stance given that 57% of its revenue comes from Servers and Storage. Huberty also downgraded NetApp (NTAP) to Underweight from Equal Weight and lowered her price target to $58 from $72, citing her view that revenue growth is likely to slow materially on more difficult compares in the coming quarters. Stating that she has a preference for hardware stocks with a higher software mix, Huberty upgraded Nutanix (NTNX) to Overweight and raised her price target to $58 from $57. Nutanix is gaining momentum as a hybrid cloud operating system provider as it adds cloud services, she tells investors. Huberty also upgraded Teradata (TDC) to Overweight from Equal Weight and raised her price target to $55 from $42. Teradata's relevance to large enterprise IT spending is on the rise with Data Warehousing and analytics rising to a top three priority in 2019, she stated.
02/11/19
PIPR
02/11/19
NO CHANGE
PIPR
Piper storage survey positive for Pure Storage, Nutanix, NetApp
Piper Jaffray conducted its fiscal Q4 Storage Reseller Survey by collecting feedback from 28 resellers and distributors. While only five of 14 vendors had net positive results versus six of the 14 last quarter, the firm saw "strong results" for Pure Storage (PSTG), Rubrik, Nutanix (NTNX), Veeam and NetApp (NTAP), analyst Andrew Nowinski told investors earlier in a research note. Pure Storage also had the strongest pipeline heading into the April quarter, added the analyst. The company's results sharply improved in the survey, with 67% of resellers citing "Above Plan" results, the highest level seen in three years, says Nowinski. The stock in early trading is up 19c to $18.47. Of those surveyed by Piper, 36% of resellers said they saw a negative impact from the U.S. government shutdown, with Dell (DELL), HP/3PAR (HPQ) and IBM (IMB) the most impacted.
01/16/19
01/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Citi (C) downgraded to Hold from Buy at Standpoint Research. 2. Snap (SNAP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Mahaney citing the company's recent "mixed" pre-announcement and, more importantly, its latest disclosure of a "surprise" exit by its CFO Tim Stone who was on the job for less than a year. 3. Nordstrom (JWN) downgraded to Neutral from Conviction Buy at Goldman Sachs, to Neutral from Overweight at Atlantic Equities, and to Market Perform from Outperform at Telsey Advisory. 4. AB InBev (BUD) downgraded to Underperform from Hold at Jefferies with analyst Edward Mundy saying market share pressures, some of which have only recently become visible, will likely persist, and could lead to disappointment against high expectations of an emerging-led recovery. 5. HP Enterprise (HPE) downgraded to Equal Weight from Overweight at Morgan Stanley, while NetApp (NTAP) was downgraded to Underweight from Equal Weight. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

EADSY

Airbus

$0.00

(0.00%)

18:36
02/18/19
02/18
18:36
02/18/19
18:36
Periodicals
Airbus warns of no-deal Brexit, Reuters reports »

Airbus said it would have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTTR

Otter Tail

$50.19

1.02 (2.07%)

18:29
02/18/19
02/18
18:29
02/18/19
18:29
Earnings
Otter Tail reports FY18 adjusted EPS $2.06, consensus $2.10 »

Reports FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

OTTR

Otter Tail

$50.19

1.02 (2.07%)

18:28
02/18/19
02/18
18:28
02/18/19
18:28
Earnings
Otter Tail reports Q4 adjusted EPS 35c, consensus 39c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

HLX

Helix Energy

$7.36

0.14 (1.94%)

18:23
02/18/19
02/18
18:23
02/18/19
18:23
Earnings
Helix Energy reports FY18 adjusted EPS 19c, consensus 23c »

Reports FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

HLX

Helix Energy

$7.36

0.14 (1.94%)

18:23
02/18/19
02/18
18:23
02/18/19
18:23
Earnings
Helix Energy reports Q4 adjusted EPS (9c), consensus (7c) »

Reports Q4 revenue $158M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

F

Ford

$8.54

0.115 (1.37%)

18:17
02/18/19
02/18
18:17
02/18/19
18:17
Periodicals
Jury awards $152M in Ford Explorer rollover case, Reuters reports »

An Alabama jury awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

GM

General Motors

$39.10

0.21 (0.54%)

, VLKAY

Volkswagen

$0.00

(0.00%)

18:14
02/18/19
02/18
18:14
02/18/19
18:14
Periodicals
U.S. Commerce Department submits auto tariff probe report, Reuters says »

The U.S. Commerce…

GM

General Motors

$39.10

0.21 (0.54%)

VLKAY

Volkswagen

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$8.54

0.115 (1.37%)

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

HMC

Honda

$27.35

0.04 (0.15%)

TM

Toyota

$121.15

1.941 (1.63%)

DDAIF

Daimler AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

FB

Facebook

$162.54

-1.4 (-0.85%)

18:10
02/18/19
02/18
18:10
02/18/19
18:10
Periodicals
Facebook says 'open to meaningful regulation,' Reuters reports »

Facebook is "open to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

BABA

Alibaba

$166.07

-2.31 (-1.37%)

18:06
02/18/19
02/18
18:06
02/18/19
18:06
Periodicals
Alibaba unit behind app for Communist Party news content, Reuters says »

A Chinese government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

FB

Facebook

$162.54

-1.4 (-0.85%)

18:01
02/18/19
02/18
18:01
02/18/19
18:01
Earnings
Facebook targeted in scathing report by British Parliament, NY Times reports »

After 18 months…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

PZZA

Papa John's

$45.28

1.71 (3.92%)

17:56
02/18/19
02/18
17:56
02/18/19
17:56
Periodicals
Papa John's founder welcomes hedge fund Starboard, Reuters reports »

Papa John's founder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$39.10

0.21 (0.54%)

, VLKAY

Volkswagen

$0.00

(0.00%)

17:53
02/18/19
02/18
17:53
02/18/19
17:53
Periodicals
Auto industry lining up against possible tariffs, Reuters reports »

The auto industry urged…

GM

General Motors

$39.10

0.21 (0.54%)

VLKAY

Volkswagen

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$8.54

0.115 (1.37%)

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

HMC

Honda

$27.35

0.04 (0.15%)

TM

Toyota

$121.15

1.941 (1.63%)

DDAIF

Daimler AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

DOOR

Masonite

$57.31

-0.07 (-0.12%)

17:41
02/18/19
02/18
17:41
02/18/19
17:41
Earnings
Masonite reports Q4 adjusted EPS 68c, consensus 80c »

Reports Q4 revenue $528M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

LECO

Lincoln Electric

$88.48

1.27 (1.46%)

17:34
02/18/19
02/18
17:34
02/18/19
17:34
Hot Stocks
Lincoln Electric Board declares quarterly dividend of 47c per common share »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 24

    Apr

RIG

Transocean

$8.93

0.395 (4.63%)

17:28
02/18/19
02/18
17:28
02/18/19
17:28
Earnings
Transocean reports Q4 EPS (34c), consensus (24c) »

Reports Q4 revenue $748M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 22

    May

CLR

Continental Resources

$46.94

1.8 (3.99%)

17:14
02/18/19
02/18
17:14
02/18/19
17:14
Earnings
Continental Resources reports Q4 adjusted 54c, consensus 62c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Mar

SPN

Superior Energy

$4.43

0.165 (3.87%)

16:53
02/18/19
02/18
16:53
02/18/19
16:53
Earnings
Superior Energy reports Q4 EPS ($4.85), may not compare consensus (0.28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

MSG

Madison Square Garden

$291.37

0.85 (0.29%)

16:46
02/18/19
02/18
16:46
02/18/19
16:46
Periodicals
MSG denies Knicks sale talks after Bill Simmons claims otherwise »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

16:45
02/18/19
02/18
16:45
02/18/19
16:45
Hot Stocks
Windstream postpones release of Q4, FY18 financial results »

Windstream announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UFPI

Universal Forest

$32.22

0.36 (1.13%)

16:43
02/18/19
02/18
16:43
02/18/19
16:43
Hot Stocks
Universal Forest signs agreement to acquire Wolverine Wood Products »

Universal Forest Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:36
02/18/19
02/18
16:36
02/18/19
16:36
Earnings
Breaking Earnings news story on Service Corp. »

Service Corp. sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:34
02/18/19
02/18
16:34
02/18/19
16:34
Earnings
Service Corp. reports Q4 adjusted EPS 54c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

APY

Apergy

$36.84

0.92 (2.56%)

16:27
02/18/19
02/18
16:27
02/18/19
16:27
Earnings
Apergy reports Q4 adjusted EPS 36c, consensus 33c »

Reports Q4 revenue of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NAVI

Navient

$11.75

0.12 (1.03%)

16:20
02/18/19
02/18
16:20
02/18/19
16:20
Hot Stocks
Navient rejects highly conditional unsolicited 'expression of interest' »

Navient announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$14.41

-0.005 (-0.03%)

16:15
02/18/19
02/18
16:15
02/18/19
16:15
Hot Stocks
24 SandBox Logistics patent claims invalidated »

Proppant Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.